Abstract: A method for the treatment of cerebrovascular disorders and/or disorders associated with cerebral senility and/or other disorders which method comprises the administration of an effective, non-toxic amount of a compound of formula (I): or if appropriate a pharmaceutically acceptable salt thereof, wherein R1 and R2 each independently represent alkyl or a moiety of formula (a): —(CH2)m−A   (a) wherein m represents zero or an integer 1, 2 or 3; A represents a substituted or unsubstituted cyclic hydrocarbon radical; and R3 represents a halogen atom, a nitro group, or a group −NR4R5 wherein R4 and R5 each independently represents hydrogen, alkyl or alkylcarbonyl or R4 and R5 together with the nitrogen to which they are attached forming an optionally substituted, heterocyclic group; certain novel compounds falling within formula (I) and compositions comprising such compounds.

Abstract: A method for the treatment of cerebrovascular disorders and/or disorders associated with cerebral senility and/or other disorders which method comprises the administration of an effective, non-toxic amount of a compound of formula (I): or if appropriate a pharmaceutically acceptable salt thereof, wherein R1 and R2 each independently represent alkyl or a moiety of formula (a): —(CH2)m-A  (a) wherein m represents zero or an integer 1, 2 or 3; A represents a substituted or unsubstituted cyclic hydrocarbon radical; and R3 represents a halogen atom, a nitro group, or a group —NR4R5 wherein R4 and R5 each independently represents hydrogen, alkyl or alkylcarbonyl or R4 and R5 together with the nitrogen to which they are attached forming an optionally substituted, heterocyclic group; certain novel compounds falling within formula (I) and compositions comprising such compounds.

Abstract: A method for the treatment of cerebrovascular disorders and/or disorders associated with cerebral senility and/or allergic disorders, proliferative skin disorders, and bronchodilation which method comprises the administration of an effective, non-toxic amount of a compound of formula (I): ##STR1## or if appropriate a pharmaceutically acceptable salt thereof, wherein R.sup.1 and R.sup.2 each independently represent alkyl or a moiety of formula (a):--(CH.sub.2).sub.m --A (a)wherein m represents zero or an integer 1, 2 or 3; A represents a substituted or unsubstituted cyclic hydrocarbon radical; andR.sup.3 represents a halogen atom, a nitro group, or a group --NR.sup.4 R.sup.5 wherein R.sup.4 and R.sup.5 each independently represents hydrogen, alkyl or alkylcarbonyl or R.sup.4 and R.sup.5 together with the nitrogen to which they are attached forming an optionally substituted, heterocyclic group; certain novel compounds falling within formula (I) and compositions comprising such compounds.

Abstract: A method for the treatment of cerebrovascular disorders and/or disorders associated with cerebral senility and/or other disorders which method comprises the administration of an effective, non-toxic amount of a compound of formula (I): ##STR1## or if appropriate a pharmaceutically acceptable salt thereof, wherein R.sup.1 and R.sup.2 each independently represent alkyl or a moiety of formula (a):--(CH.sub.2).sub.m --A (a)whereinm represents zero or an integer 1, 2 or 3;A represents a substituted or unsubstituted cyclic hydrocarbon radical; andR.sup.3 represents a halogen atom, a nitro group, or a group --NR.sup.4 R.sup.5 wherein R.sup.4 and R.sup.5 each independently represents hydrogen, alkyl or alkylcarbonyl or R.sup.4 and R.sup.5 together with the nitrogen to which they are attached forming an optionally substituted, heterocyclic group; certain novel compounds falling within formula (I) and compositions comprising such compounds.

Abstract: A method of treatment or prophylaxis of angina in mammals, such as humans, which comprises the administration to the sufferer of an effective amount of a compound of formula (I), or a pharmaceutically acceptable salt thereof, or a solvate of any of the foregoing: ##STR1## wherein R.sub.1, R.sub.2, R.sub.3, R.sub.4, A and B are herein defined.

Abstract: A method of treatment or prophylaxis of angina in mammals, such as humans, which comprises the administration to the sufferer of an effective amount of a compound of formula (I), or a pharmaceutically acceptable salt thereof, or a solvate of any of the foregoing: ##STR1## wherein R.sub.1, R.sub.2, R.sub.3, R.sub.4, A and B are herein defined.

Abstract: A compound of formula (I) or a pharmaceutically acceptable salt thereof: ##STR1## wherein: R.sub.1 is --CH.sub.3 or --CH.sub.2 CH.sub.3 unsubstituted or substituted by 1 to 3 fluorines;X is O or S(O).sub.s where s=0 to 2;R.sub.2 is C.sub.4 -C.sub.6 cyclic alkyl, optionally substituted by one to three methyl groups or one ethyl group; --CH.sub.2 -cyclopentyl, --CH.sub.2 -cyclopropyl, 3-tetrahydrofuranyl, C.sub.1-7 alkyl, CH.sub.3 or CH.sub.2 CH.sub.3 substituted by one to three fluorines;--(CH.sub.2).sub.n COO(CH.sub.2).sub.g CH.sub.3, or (CH.sub.2).sub.n O(CH.sub.2).sub.g CH.sub.3, wherein n is 2 to 4 and g is 0 to 2;R.sub.3 represents a moiety of formula (a); ##STR2## wherein R.sub.4 and R.sub.5 each represent hydrogen or R.sub.4 and R.sub.5 together represent a bond;B represents >C.dbd.O, >C.dbd.S or >CH--R.sub.6 wherein R.sub.6 represents H, OH, C.sub.1-6 alkoxy or C.sub.

Abstract: A compound of formula (I): ##STR1## or where appropriate a pharmaceutically acceptable salt thereof, wherein R.sup.1 and R.sup.2 each independently represent a moiety of formula (a):--(CH.sub.2).sub.m --A (a)wherein m represents zero or an integer 1, 2 or 3, A represents a substituted or unsubstituted cyclic hydrocarbon radical; andR.sup.3 represents hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl or a moiety of formula (a) as defined above; a pharmaceutical composition comprising such a compound a process for preparing such a compound and the use of said compound and said composition in medicine.

Abstract: Compounds of the formula (I): ##STR1## and pharmaceutically acceptable acid addition salts thereof, wherein,Ar is optionally substituted phenyl or naphthyl, or pyridyl;E is O, S or a bond;R.sub.5 is hydrogen, andJ is C.sub.3-5 polymethylene, optionally substituted by one or two groups selected from methyl or optionally derivatized hydroxy; orAr and R.sub.5 together form a group ##STR2## where Ar.sup.1 is optionally substituted 1,2-phenylene;Z is O or CH.sub.2, andm is 0 or 1, when E is O or S, or 1 when E is bond;R.sub.1 is hydrogen, C.sub.1-4 alkyl optionally substituted phenyl; C.sub.3-8 alkanoyl, or phenyl C.sub.2-8 alkanoyl, any phenyl moiety being optionally substituted; a group COR.sub.2 where R.sub.2 is C.sub.2-3 alkoxy, phenyl C.sub.1-4 alkoxy, the phenyl moiety being optionally substituted, or C.sub.1-4 alkoxy C.sub.3-4 alkoxy; or a group CXNHR.sub.3 where X is O or S and R.sub.3 is C.sub.2-4 alkyl, C.sub.2-4 alkenyl, phenyl or phenyl C.sub.